Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel

CANNANNEW REPORT

Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the pre-launch of its first-generation medical cannabis inflorescence products. Evogene Logo (PRNewsfoto/Evogene) G-nnovation first products G-nnovation first products Canonic’s first product line, G-nnovation, is based on cannabis varieties that were selected and developed to express high levels of THC[1] and premium consumer traits. As part of the pre-launch, G-nnovation products will be marketed in Israel to a limited number of licensed patients through Telepharma pharmacy, with whom Canonic recently engaged. Full commercial product launch in Israel is expected in 2022. The pre-launch follows the successful completion of selection and development of the first-generation G-nnovation product line under Canonic’s Meta Yield product program, the approval of The Israel Medical Cannabis Authority (IMCA) of the product files, and the establishment of commercialization channels. With this, Canonic has completed its end-to-end cannabis value chain in Israel, from seed to product. According to recent statistics, in July 2021 there were approximately 100,000 licensed patients in Israel that consumed approximately 20 tons of cannabis in the first 6 months of the year[2], with a total medical cannabis market in Israel estimated at $260 million per year[3]. According to industry estimates, based on current growth rates, the Israeli market will reach approximately 250,000 patients by 2025.[4] Dr. Arnon Heyman, CEO of Canonic stated: “We are very excited to launch our first products in the Israeli market. We achieved this milestone in a very short time due to our experienced team and strong computational biology capabilities. I see this as our first step in fulfilling our vision to become a leading global medical cannabis company. The initial launch in the Israeli market is only the beginning of our journey towards penetration to additional markets abroad.” Mr. Ofer Haviv, Chairman of Canonic and CEO & President of Evogene, stated:…

Excerpt only …
READ MORE BELOW
Source : Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.